BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Revvity expands access to base editing technology

28 September 2023 | News

Launch of Pin-point base editing reagents improves access to new-generation editing technology

American firm Revvity, Inc. has unveiled its groundbreaking Pin-point base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories.

Base editing represents a pivotal advancement in CRISPR gene editing, providing the capability for complex and safe multi-gene editing, which can result in enhanced functional genomics insights for optimising drug development, as well as streamlining cell line and cell therapy development and manufacturing. The Pin-point platform is one of the few established base editing technologies currently being employed in clinical settings, positioning it as both a discovery and therapeutic tool.

The initial reagents launch includes mRNAs for nCas9 and rat APOBEC, as well as three guide RNAs designed to knockout the TRAC, CD52 and PDCD1 loci. These reagents have undergone extensive validation and have demonstrated their performance in T-cells and induced pluripotent stem cells (iPSCs). Furthermore, Revvity offers the flexibility of ordering custom guides for other targets through its Dharmacon custom gRNA ordering tool for the Pin-point base editing platform, supporting diverse research applications.

The introduction of Pin-point base editing reagents signifies a momentous stride toward democratising access to base editing. Until now, base editing reagents were either custom-ordered by end-users or obtained by non-profit laboratories as individual components. However, with the newly launched reagents, scientists now have the ability to fully evaluate the Pin-point base editing platform in-house.